Advertisement


Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Advertisement